Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C financing. The company anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.  The Series C financing was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. With the financing, Dr. Norman Zhou of Boxer Capital has joined the board of directors at Vivace. About Vivace Therapeutics, Inc. Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need. Based in San Francisco Bay Area, the company has raised $70 million to date, and is funded by leading biotechnology investors, including Canaan Partners, WuXi Healthcare Ventures, Cenova Capital, Sequoia Capital China, Boxer Capital and RA Capital Mangement. For more information, please visit www.vivacetherapeutics.com. Boxer Capital is a private biotechnology investment fund based in San Diego, California that invents and invests in new therapeutics across multiple indications in order to create value through improved patient care and outcomes.  Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital invests in private and public companies representing the entire drug development lifecycle from early-stage preclinical discovery assets to late-stage clinical and commercial stage companies. For more information, please visit www.boxercap.com.
（以上内容由医药魔方AI生成）